
NEWS RELEASE

ix Biopharma secures Israel patent for WaferiX™ drug delivery technology

- ✓ *The US patent over WaferiX™ has also been issued by the United States Patent and Trademark Office*
- ✓ *WaferiX™ is now protected in 30 countries across 5 continents*

Singapore, 21 September 2020 – Specialty pharmaceutical company **ix Biopharma Ltd** (SGX:42C) (“ix Biopharma” or “the Company”, and together with its subsidiaries, “the Group”) is pleased to announce that it has been granted a patent in Israel (Patent no. 238104) for its **WaferiX™** drug delivery technology. The patent will expire on 11 October 2033 and will provide key intellectual property protection for the Company's WaferiX™ delivery technology platform in Israel.

Further, ix Biopharma wishes to update that following its announcement on 9 June 2020 that it had received a notice of allowance from the United States Patent and Trademark Office for WaferiX™ (U.S. Patent Application No 13/504,309), the patent has now been issued as Patent no. 10,744,086. The patent will expire on 26 October 2030.

WaferiX™ is a multiple drug carrier platform technology that allows pharmacologically active compounds, such as ketamine and sildenafil, to be administered sublingually (i.e. placed under the tongue) and delivered safely, conveniently and rapidly into the blood stream.

Produced via the Group's proprietary freeze-drying technique, the porous and amorphous WaferiX™ matrix holding the active molecules is designed to collapse quickly within the sublingual space before being transported rapidly across the sublingual membrane into the blood vessels for a rapid onset of action. In addition, the technology has also been proven to increase the bioavailability of drug actives as well as predictability of effect.

With Israel's grant of patent, ix Biopharma's intellectual property rights for its sublingual wafer technology is now secured in 5 continents and all key markets including the United States, China, Australia, New Zealand, Singapore, Japan, South Korea, India, Malaysia, and Indonesia, countries in the European Union and others.

- The End -

About iX Biopharma Ltd

iX Biopharma is a specialty pharmaceutical and nutraceutical company listed on the Catalist board of the Stock Exchange of Singapore (SGX-ST), operating a fully integrated business model from drug development to manufacturing and supply, with facilities in Australia. The Group is focused on the development and commercialisation of therapies for diseases of the central nervous system using novel, patent-protected formulations for sublingual delivery.

iX Biopharma's pipeline of products under development includes Wafermine (ketamine wafer) and BnoX (buprenorphine wafer) for pain management. iX Biopharma's drugs for the treatment of erectile dysfunction, Wafesil, a sublingual sildenafil wafer, and Silcap, have been registered in Australia. iX Biopharma has developed Xativa, the world's first freeze-dried sublingual medicinal cannabis wafer.

The Group's nutraceuticals division, Entity Health Limited, is engaged in the development and commercialisation of nutraceutical products that address specific conditions and improve quality of life. It distributes its Entity line of nutraceutical products in Australia through more than 250 pharmacies and health food shops, in China through its flagship stores on Tmall Global and JD Worldwide, and globally through its online store.

Contact for media:

Dr Janakan Krishnarajah

Chief Operating Officer and Chief Medical Officer

T: +65 6235 2270

E: j.krishnarajah@ixbiopharma.com

Eva Tan

Director, Corporate and Commercial Strategy

T: +65 6235 3212

E: eva.tan@ixbiopharma.com

Investor Relations:

Kamal Samuel/Jonathan Wee

T: +65 6438 2990

E: Tech@financialpr.com.sg

This announcement has been reviewed by the Company's sponsor, CIMB Bank Berhad, Singapore Branch ("**Sponsor**") in accordance with Rule 226(2)(b) of the Catalist Rules. This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr. Yee Chia Hsing, Head, Catalist. The contact particulars are 50 Raffles Place, #09-01 Singapore Land Tower, Singapore 048623, telephone: (65) 6337-5115.
